What is Theravance Biopharma's stock-based comp?

Theravance Biopharma (TBPH) reported stock-based comp of $4.5M in Q1 2026.

How has Theravance Biopharma's stock-based comp changed year-over-year?

Theravance Biopharma's stock-based comp decreased by 7.6% year-over-year, from $4.88M to $4.5M.

What is the long-term trend for Theravance Biopharma's stock-based comp?

Over 4 years (2021 to 2025), Theravance Biopharma's stock-based comp has grown at a -26.1% compound annual growth rate (CAGR), from $62.06M to $18.48M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Theravance Biopharma TBPH Stock-Based Comp

Stock-Based Comp at other companies

Zevra Therapeutics, Inc.ZVRA

$3.11M-0.3%

LQD

Liquidia CorporationLQDA

$9.22M+23.9%

United TherapeuticsUTHR

$33.9M+6.6%

Aurinia PharmaceuticalsAUPH

-$866K+74.6%

PrecigenPGEN

$3.01M+12.3%

OrganonOGN

$19M-20.8%

Segments

By segment

See full

Single Reportable$3.48M-28.7%

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$896.51M+68.7%

Enterprise value$648.91M+38.3%

P/E7.8×—

P/S8.2×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's stock-based comp?: Theravance Biopharma (TBPH) reported stock-based comp of $4.5M in Q1 2026.
How has Theravance Biopharma's stock-based comp changed year-over-year?: Theravance Biopharma's stock-based comp decreased by 7.6% year-over-year, from $4.88M to $4.5M.
What is the long-term trend for Theravance Biopharma's stock-based comp?: Over 4 years (2021 to 2025), Theravance Biopharma's stock-based comp has grown at a -26.1% compound annual growth rate (CAGR), from $62.06M to $18.48M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.